No description available.

No description available.

No description available.

In order to elucidate how uncoupling protein 2 (UCP2) influences pancreatic β cells and glucose homeostasis, I have generated and characterized an inducible β cell-specific UCP2 deletion model,MIPCreER×loxUCP2 mice. Male littermates were injected with tamoxifen to induce UCP2 deletion(UCP2 iBKO) or with corn oil (CO). The phenotypes of both short-term (3-4 weeks after the last injection) and long-term (8-9 weeks after the last injection) were determined: Short-term iBKO mice displayed no differences in glucose or insulin tolerance, but enhanced in vivo and in vitro insulin secretion and suppressed islet reactive oxygen species (ROS) levels; while long-term iBKO mice displayed no difference in glucose tolerance, but impaired in vivo and in vitro insulin secretion and enhanced islet ROS levels. In conclusion, short-term UCP2 deletion in β cells promotes insulin secretion, while long-term UCP2 deletion impairs insulin secretion, possibly due to the opposite background of islet ROS.

In order to elucidate how uncoupling protein 2 (UCP2) influences pancreatic β cells and glucose homeostasis, I have generated and characterized an inducible β cell-specific UCP2 deletion model,MIPCreER×loxUCP2 mice. Male littermates were injected with tamoxifen to induce UCP2 deletion(UCP2 iBKO) or with corn oil (CO). The phenotypes of both short-term (3-4 weeks after the last injection) and long-term (8-9 weeks after the last injection) were determined: Short-term iBKO mice displayed no differences in glucose or insulin tolerance, but enhanced in vivo and in vitro insulin secretion and suppressed islet reactive oxygen species (ROS) levels; while long-term iBKO mice displayed no difference in glucose tolerance, but impaired in vivo and in vitro insulin secretion and enhanced islet ROS levels. In conclusion, short-term UCP2 deletion in β cells promotes insulin secretion, while long-term UCP2 deletion impairs insulin secretion, possibly due to the opposite background of islet ROS.

No description available.

Abstract The purpose of this work was to assess the value of humoral and genetic risk markers in the prediction of type 1 diabetes in siblings of children with type 1 diabetes, to characterise preclinical course of beta-cell autoimmunity in siblings, and to investigate the frequency of autoantibodies and their relations to genetic markers, beta-cell function and progression to type 1 diabetes in a schoolchild population. The prevalence and predictive value of autoantibodies was studied in 755 initially unaffected siblings, and the combination of genetic markers and autoantibodies in 701 of these siblings. Islet cell autoantibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase antibodies (GADA) and IA-2 antibodies (IA-2A) were all shown to be of value in the prediction of type 1 diabetes in siblings initially tested at or close to the diagnosis of type 1 diabetes in the index case in the family. The risk of progression to type 1 diabetes was related to the number of autoantibodies detected, and the PPV of multiple autoantibodies was 55% over a period of 8 years. Autoantibodies were closely associated with HLA risk markers. A combination of the genetic markers and autoantibodies increased the PPVs of all autoantibodies substantially but also markedly reduced the sensitivity. The preclinical course of type 1 diabetes was investigated in 39 initially unaffected siblings who progressed to clinical disease during the follow-up. These individuals were characterised by the high-risk genetic markers, decreased beta-cell function and humoral autoimmunity against multiple beta-cell targets. However, all measures implied a remarkable individual variation in the rate of the disease process and the pattern of humoral beta-cell autoimmunity. Furthermore, the autoimmune process resulting in clinical presentation of type 1 diabetes could not be unambiguously distinguished from autoimmunity not leading to clinical disease within almost 10 years of follow-up. The frequencies of ICA, IA-2A, GADA and IAA in 3652 healthy Finnish schoolchildren were 2.8%, 0.6%, 0.5% and 0.9%, respectively, and multiple antibodies were detected in 0.6% of these children. GADA and multiple antibodies were related to the DQB1*0302 allele and the DQB1*02/0302 genotype. A reduced first-phase insulin reponse (FPIR) was associated with IA-2A, GADA, IAA and multiple antibodies, but not with ICA or any specific DQB1 allele or genotype. Four subjects progressed to type 1 diabetes, all of them having multiple autoantibodies and those two who underwent an intravenous glucose tolerance test had also a reduced FPIR. None of the progressors carried the high risk DQB1*0302 allele and two of them even carried the protective DQB1*0602 or *0603 allele. In conclusion, autoantibodies alone are recommended as first-line screening in siblings, whereas subsequent determination of HLA-DQB1 markers and their combination with autoantibodies provides a valuable tool for more precise risk assessment. Wide heterogeneity in the course of preclinical type 1 diabetes complicates an accurate estimation of the individual risk of progression to type 1 diabetes among siblings of children with type 1 diabetes. Combined screening for autoantibodies is recommended for the assessment of the risk of progression to type 1 diabetes in schoolchild populations, whereas the present observations challenge the value of current genetic risk markers in predictive strategies targeting schoolchildren.

No description available.

京都大学 / 新制・課程博士 / 博士(工学) / 甲第23161号 / 工博第4805号 / 新制||工||1751(附属図書館) / 京都大学大学院工学研究科高分子化学専攻 / (主査)教授 田畑 泰彦, 教授 秋吉 一成, 教授 沼田 圭司 / 学位規則第4条第1項該当 / Doctor of Philosophy (Engineering) / Kyoto University / DFAM

<p> Fetal exposure to cigarette smoke is associated with an increased risk of adult-onset metabolic abnormalities. In Canada, nicotine replacement therapy (NRT) is recommended as a safe smoking cessation aid for pregnant women. However, our laboratory has demonstrated that fetal and neonatal nicotine exposure results in glucose intolerance in adult rats. The goal of this thesis was to determine the mechanism(s) underlying the observed dysglycemia following fetal and neonatal nicotine exposure, with a specific focus on the effects of nicotine on pancreatic development and postnatal beta cell function.</p> <p> Nulliparous female Wistar rats received daily subcutaneous injections of either saline or nicotine bitartrate (1 mg/kg/d) for 2 weeks prior to mating until weaning (postnatal day 21 - PND21 ). Pancreatic tissue was collected from male offspring at birth (PND1), 3, 7, 15 and 26 weeks of age. For the critical windows study, dams received nicotine or saline during different stages of pancreatic development, including: A) pre-mating only, B) pre-mating + pregnancy only, C) pre-mating, pregnancy and lactation, or D) pre-mating + lactation only. For the intervention study, nicotine-exposed dams received either normal chow or diet containing antioxidants (1000 IU/kg vitamin E, 0.25% w/w coenzyme Q10 and 0.05% w/w α-lipoic acid) during mating, pregnancy and lactation.</p> <p> Results from this thesis demonstrate that exposure to nicotine during both fetal and neonatal development (but neither stage alone) causes a permenant loss of beta cell mass beginning at birth, and adult-onset dysglycemia in rodents. Furthermore, nicotine exposure induces pancreatic oxidative stress and mitochondrial-mediated beta cell apoptosis in neonates, followed by a progressive decline in mitochondrial structure and function. Maternal treatment with a dietary antioxidant cocktail during pregnancy and lactation protected the developing beta cells from nicotine-induced apoptosis and mitochondrial swelling. These data indicate that the safety of NRT use during pregnancy should be re-evaluated.</p> / Thesis / Doctor of Philosophy (PhD)